Project Grant R01HL183385
Award Date 8/1/26
Completion Date 4/30/30
Dollars Obligated $800K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Brooklyn, NY 11203, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded The Research Foundation for the State University of New York $502,773 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and evaluate docosahexaenoic acid (DHA)-loaded nanoparticles as an inflammation resolution therapy targeting acute lung injury and acute respiratory distress syndrome. The research addresses the clinical challenge that anti-inflammatory agents—the current standard approach to...
- The National Heart, Lung, and Blood Institute awarded New York University's Long Island School of Medicine $2.728 million on September 24, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on reducing plasma cholesterol and atherosclerosis using C2, a synthetic microRNA-30c analog. The research will elucidate molecular mechanisms by which C2 administration reduces plasma cholesterol levels in mice with diet-induced hypercholesterolemia and LDL receptor...
- The National Heart, Lung, and Blood Institute awarded $448,250 to The Research Foundation For The State University Of New York on May 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and evaluate a lung-targeted immunomodulatory messenger RNA therapy for acute respiratory distress syndrome. The award funds development of an IL-10 mRNA therapeutic delivered via sulfonium lipid nanoparticles, a novel lung-targeting technology designed to suppress...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Research Foundation For The State University Of New York $2,745,108 on September 11, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847, Project Grant R01DK143260). The recipient will develop microfluidic devices that replicate the dimensions and branched structures of human kidney vasculature to investigate systemic amyloidosis. The devices will subject...
- The National Heart, Lung, and Blood Institute awarded New York University $763,960 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the molecular mechanisms by which long non-coding RNA IRF1-AS1 and its mouse ortholog GM12216 regulate atherosclerotic cardiovascular disease. The research will examine how IRF1-AS1 coordinates expression of protein-coding genes including the transcriptional regulator IRF1 in myeloid cells to drive atherogenesis,...
- The National Heart, Lung, and Blood Institute awarded Weill Medical College of Cornell University a Project Grant (K99HL181309) of $129,600 on June 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to characterize a novel mechanism of atherosclerosis development. The funded research investigates digestive exophagy, a process by which macrophages form extracellular, acidic compartments to hydrolyze aggregated low-density lipoprotein that is bound to the extracellular...
- Federal Project Grant Award Summary Stony Brook University, operating through The Research Foundation For The State University Of New York, received a $237,750 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The award, effective September 1, 2025 through August 31, 2027, supports research investigating the association between circulating blood biomarkers and adverse cardiovascular and kidney outcomes...
- The National Institute of General Medical Sciences awarded The Research Foundation For The State University of New York $434,892 on September 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to support structural and biosynthetic research on natural product enzymes. The award funds investigation of nonribosomal peptide synthetases (NRPSs) and NRPS-independent siderophore biosynthetic pathways, with focus on the conformational dynamics that NRPSs employ to...
- The National Heart, Lung, and Blood Institute awarded Albany Medical College $586,474 under CFDA 93.837 (Cardiovascular Diseases Research) on June 15, 2026, to investigate lipolytic sterol signaling mechanisms in foam cell modulation and atherosclerosis prevention. The project targets lipid droplet-associated hydrolase (LDAH) as a regulator of adaptive responses to lipid overload in atherosclerotic lesions. Research will examine how LDAH mobilizes sterol stores within cytoplasmic lipid...
- The National Heart, Lung, and Blood Institute awarded Louisiana State University Health Sciences Center-Shreveport $111,111 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate mechanisms linking endoplasmic reticulum stress, lipid accumulation, and vascular inflammation in atherosclerosis. The research defines how the NCK1 adaptor protein integrates mechanical and metabolic stress to drive endothelial dysfunction. Aim 1 investigates how NCK1...